First Time Loading...

Santen Pharmaceutical Co Ltd
TSE:4536

Watchlist Manager
Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd
TSE:4536
Watchlist
Price: 1 512.5 JPY 1.41% Market Closed
Updated: Apr 30, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Santen Pharmaceutical Co Ltd

Wall Street analysts forecast Santen Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Santen Pharmaceutical Co Ltd is 1 753.27 JPY with a low forecast of 1 313 JPY and a high forecast of 2 121 JPY.

Lowest Forecast
Wall Street Target
1 313 JPY
13% Downside
Average Forecast
Wall Street Target
1 753.27 JPY
16% Upside
Highest Forecast
Wall Street Target
2 121 JPY
40% Upside
Lowest
Price Target
1 313 JPY
13% Downside
Average
Price Target
1 753.27 JPY
16% Upside
Highest
Price Target
2 121 JPY
40% Upside
Santen Pharmaceutical Co Ltd Competitors:
Price Targets
L
503
Lansen Pharmaceutical Holdings Ltd
78% Downside
001060
JW Pharmaceutical Corp
49% Upside
600557
Jiangsu Kanion Pharmaceutical Co Ltd
31% Upside
J
300497
Jiangxi Fushine Pharmaceutical Co Ltd
180% Upside
L
503
Lansen Pharmaceutical Holdings Ltd
78% Downside
001060
JW Pharmaceutical Corp
49% Upside
600557
Jiangsu Kanion Pharmaceutical Co Ltd
31% Upside
J
300497
Jiangxi Fushine Pharmaceutical Co Ltd
180% Upside
063160
CKD Bio Corp
11% Upside
K
GUD
Knight Therapeutics Inc
17% Upside
N
4516
Nippon Shinyaku Co Ltd
78% Upside
SEQUENT
SeQuent Scientific Ltd
6% Upside

Revenue
Forecast

Revenue Estimate
Santen Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Santen Pharmaceutical Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 2%.

7%
Past Growth
2%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Santen Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Santen Pharmaceutical Co Ltd's operating income is 0%. The projected CAGR for the next 3 years is 14%.

0%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-27%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Santen Pharmaceutical Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Santen Pharmaceutical Co Ltd's stock price target?
Price Target
1 753.27 JPY

According to Wall Street analysts, the average 1-year price target for Santen Pharmaceutical Co Ltd is 1 753.27 JPY with a low forecast of 1 313 JPY and a high forecast of 2 121 JPY.

What is Santen Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
2%

For the last 8 years the compound annual growth rate for Santen Pharmaceutical Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 2%.

What is Santen Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Santen Pharmaceutical Co Ltd's operating income is 0%. The projected CAGR for the next 3 years is 14%.

ALPHA SPREAD
Join more than 132,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.